THIRD HARMONIC BIO INC (THRD)

US88427A1079 - Common Stock

13.865  -0.37 (-2.57%)

After market: 13.865 0 (0%)

News Image
4 days ago - InvestorPlace

THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q1 2024

THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the first quarter of 2024.

News Image
5 days ago - Third Harmonic Bio

Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results...

News Image
2 months ago - Third Harmonic Bio

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

News Image
2 months ago - InvestorPlace

THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023

THRD stock results show that Third Harmonic Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24

News Image
3 months ago - Third Harmonic Bio

Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

News Image
3 months ago - Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...

News Image
4 months ago - Market News Video

Third Harmonic Bio is Now Oversold (THRD)

News Image
5 months ago - Seeking Alpha

Third Harmonic appoints Christopher Murphy as CFO (NASDAQ:THRD)

Third Harmonic Bio appoints Christopher Murphy as Chief Financial and Business Officer, signaling progress towards their Phase 1 study on THB335.

News Image
6 months ago - Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The...

News Image
6 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Third Quarter 2023 Financial Results

On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with...

News Image
7 months ago - Seeking Alpha

Third Harmonic Bio says CFO Robert Ho to leave co (NASDAQ:THRD)

THRD announces CFO's departure and CSO's transition in executive positions.

News Image
7 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Leadership Changes

News Image
7 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Leadership Changes

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

News Image
8 months ago - Seeking Alpha

Third Harmonic Bio files for a mixed shelf offering of $400M (NASDAQ:THRD)

THRD filed a mixed shelf prospectus to potentially raise $400M.

News Image
9 months ago - Third Harmonic Bio

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave...

News Image
9 months ago - Seeking Alpha

(NASDAQ:THRD)

Third Harmonic Bio press release (THRD): Q2 GAAP EPS of $0.42.

News Image
9 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Second Quarter 2023 Financial Results

Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor,...

News Image
10 months ago - Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Third Harmonic Bio, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

News Image
10 months ago - Third Harmonic Bio

Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical...

News Image
a year ago - Third Harmonic Bio

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases

News Image
a year ago - Third Harmonic Bio

Third Harmonic Bio Announces First Quarter 2023 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases...

News Image
a year ago - Third Harmonic Bio

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases

News Image
a year ago - Third Harmonic Bio

Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results

Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases...